4.6 Article

An In Vivo Platform for Tumor Biomarker Assessment

Journal

PLOS ONE
Volume 6, Issue 10, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0026722

Keywords

-

Funding

  1. Department of Defense Research Grant, Mesothelioma Applied Research Foundation (MARF) [PR101053]
  2. Commonwealth Foundation for Cancer Research
  3. Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center
  4. American Association for Thoracic Surgery (AATS)
  5. IASLC - International Association for the Study of Lung Cancer Young Investigator
  6. National Lung Cancer Partnership/LUNGevity Foundation
  7. Stony Wold-Herbert Fund, New York State Empire Clinical Research Investigator Program (ECRIP)
  8. National Cancer Institute [U54CA137788/U54CA132378]
  9. CDMRP [547075, PR101053] Funding Source: Federal RePORTER

Ask authors/readers for more resources

Tumor biomarkers provide a quantitative tool for following tumor progression and response to therapy. However, investigations of clinically useful tumor biomarkers are time-consuming, costly, and limited by patient and tumor heterogeneity. In addition, assessment of biomarkers as indicators of therapy response is confounded by the concomitant use of multiple therapeutic interventions. Herein we report our use of a clinically relevant orthotopic animal model of malignant pleural mesothelioma for investigating tumor biomarkers. Utilizing multi-modality imaging with correlative histopathology, we demonstrate the utility and accuracy of the mouse model in investigating tumor biomarkers - serum soluble mesothelin-related peptide (SMRP) and osteopontin (OPN). This model revealed percentage change in SMRP level to be an accurate biomarker of tumor progression and therapeutic response - a finding consistent with recent clinical studies. This in vivo platform demonstrates the advantages of a validated mouse model for the timely and cost-effective acceleration of human biomarker translational research.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available